Karin A L Mueller1,2, David B Hanna3, Erik Ehinger1, Xiaonan Xue3, Livia Baas1,2, Meinrad P Gawaz2, Tobias Geisler2, Kathryn Anastos3, Mardge H Cohen4, Stephen J Gange5, Sonya L Heath6, Jason M Lazar7, Chenglong Liu8, Wendy J Mack9, Igho Ofotokun10, Phyllis C Tien11, Howard N Hodis9, Alan L Landay12, Robert C Kaplan3,13, Klaus Ley1. 1. La Jolla Institute of Immunology, Athena Circle Drive La Jolla, CA, USA. 2. Eberhard Karls University, Tuebingen University Hospital, Department of Cardiology, Otfried-Mueller-Strasse 10, Tuebingen, Germany. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Belfer 13th floor, Bronx, NY, USA. 4. John H. Stroger, Jr. Hospital of Cook County, 1969 Ogden Ave, Chicago, IL, USA. 5. Department of Epidemiology, Johns Hopkins University, 265 Garland Hall, 3400 North Charles Street, Baltimore, MD, USA. 6. Department of Medicine, University of Alabama at Birmingham, 908 20th Street South, Birmingham, AL, USA. 7. Department of Medicine, SUNY-Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY, USA. 8. Georgetown University Medical Center, Washington, DC, USA. 9. Department of Preventive Medicine, University of Southern California, 2001 N Soto St, Los Angeles, CA, USA. 10. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 49 Jesse Hill Jr. Drive, Atlanta, GA, USA. 11. Department of Medicine, VAMC, Infectious Disease Section, 111W 4150 Clement St., San Francisco, CA, USA. 12. Department of Internal Medicine, Rush University Medical Center, 1735 West Harrison St, Chicago, IL, USA. 13. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abstract
AIMS: To test whether human immunodeficiency virus (HIV) infection and subclinical cardiovascular disease (sCVD) are associated with expression of CXCR4 and other surface markers on classical, intermediate, and non-classical monocytes in women. METHODS AND RESULTS: sCVD was defined as presence of atherosclerotic lesions in the carotid artery in 92 participants of the Women's Interagency HIV Study (WIHS). Participants were stratified into four sets (n = 23 each) by HIV and sCVD status (HIV-/sCVD-, HIV-/sCVD+, HIV+/sCVD-, and HIV+/sCVD+) matched by age, race/ethnicity, and smoking status. Three subsets of monocytes were determined from archived peripheral blood mononuclear cells. Flow cytometry was used to count and phenotype surface markers. We tested for differences by HIV and sCVD status accounting for multiple comparisons. We found no differences in monocyte subset size among the four groups. Expression of seven surface markers differed significantly across the three monocyte subsets. CXCR4 expression [median fluorescence intensity (MFI)] in non-classical monocytes was highest among HIV-/CVD- [628, interquartile range (IQR) (295-1389)], followed by HIV+/CVD- [486, IQR (248-699)], HIV-/CVD+ (398, IQR (89-901)), and lowest in HIV+/CVD+ women [226, IQR (73-519)), P = 0.006 in ANOVA. After accounting for multiple comparison (Tukey) the difference between HIV-/CVD- vs. HIV+/CVD+ remained significant with P = 0.005 (HIV-/CVD- vs. HIV+/CVD- P = 0.04, HIV-/CVD- vs. HIV-/CVD+ P = 0.06, HIV+/CVD+ vs. HIV+/CVD- P = 0.88, HIV+/CVD+ vs. HIV-/CVD+ P = 0.81, HIV+/CVD- vs. HIV-/CVD+, P = 0.99). All pairwise comparisons with HIV-/CVD- were individually significant (P = 0.050 vs. HIV-/CVD+, P = 0.028 vs. HIV+/CVD-, P = 0.009 vs. HIV+/CVD+). CXCR4 expression on non-classical monocytes was significantly higher in CVD- (501.5, IQR (249.5-887.3)) vs. CVD+ (297, IQR (81.75-626.8) individuals (P = 0.028, n = 46 per group). CXCR4 expression on non-classical monocytes significantly correlated with cardiovascular and HIV-related risk factors including systolic blood pressure, platelet and T cell counts along with duration of antiretroviral therapy (P < 0.05). In regression analyses, adjusted for education level, study site, and injection drug use, presence of HIV infection and sCVD remained significantly associated with lower CXCR4 expression on non-classical monocytes (P = 0.003), but did not differ in classical or intermediate monocytes. CONCLUSION: CXCR4 expression in non-classical monocytes was significantly lower among women with both HIV infection and sCVD, suggesting a potential atheroprotective role of CXCR4 in non-classical monocytes. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To test whether human immunodeficiency virus (HIV) infection and subclinical cardiovascular disease (sCVD) are associated with expression of CXCR4 and other surface markers on classical, intermediate, and non-classical monocytes in women. METHODS AND RESULTS: sCVD was defined as presence of atherosclerotic lesions in the carotid artery in 92 participants of the Women's Interagency HIV Study (WIHS). Participants were stratified into four sets (n = 23 each) by HIV and sCVD status (HIV-/sCVD-, HIV-/sCVD+, HIV+/sCVD-, and HIV+/sCVD+) matched by age, race/ethnicity, and smoking status. Three subsets of monocytes were determined from archived peripheral blood mononuclear cells. Flow cytometry was used to count and phenotype surface markers. We tested for differences by HIV and sCVD status accounting for multiple comparisons. We found no differences in monocyte subset size among the four groups. Expression of seven surface markers differed significantly across the three monocyte subsets. CXCR4 expression [median fluorescence intensity (MFI)] in non-classical monocytes was highest among HIV-/CVD- [628, interquartile range (IQR) (295-1389)], followed by HIV+/CVD- [486, IQR (248-699)], HIV-/CVD+ (398, IQR (89-901)), and lowest in HIV+/CVD+ women [226, IQR (73-519)), P = 0.006 in ANOVA. After accounting for multiple comparison (Tukey) the difference between HIV-/CVD- vs. HIV+/CVD+ remained significant with P = 0.005 (HIV-/CVD- vs. HIV+/CVD- P = 0.04, HIV-/CVD- vs. HIV-/CVD+ P = 0.06, HIV+/CVD+ vs. HIV+/CVD- P = 0.88, HIV+/CVD+ vs. HIV-/CVD+ P = 0.81, HIV+/CVD- vs. HIV-/CVD+, P = 0.99). All pairwise comparisons with HIV-/CVD- were individually significant (P = 0.050 vs. HIV-/CVD+, P = 0.028 vs. HIV+/CVD-, P = 0.009 vs. HIV+/CVD+). CXCR4 expression on non-classical monocytes was significantly higher in CVD- (501.5, IQR (249.5-887.3)) vs. CVD+ (297, IQR (81.75-626.8) individuals (P = 0.028, n = 46 per group). CXCR4 expression on non-classical monocytes significantly correlated with cardiovascular and HIV-related risk factors including systolic blood pressure, platelet and T cell counts along with duration of antiretroviral therapy (P < 0.05). In regression analyses, adjusted for education level, study site, and injection drug use, presence of HIV infection and sCVD remained significantly associated with lower CXCR4 expression on non-classical monocytes (P = 0.003), but did not differ in classical or intermediate monocytes. CONCLUSION: CXCR4 expression in non-classical monocytes was significantly lower among women with both HIV infection and sCVD, suggesting a potential atheroprotective role of CXCR4 in non-classical monocytes. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: C Weber; K U Belge; P von Hundelshausen; G Draude; B Steppich; M Mack; M Frankenberger; K S Weber; H W Ziegler-Heitbrock Journal: J Leukoc Biol Date: 2000-05 Impact factor: 4.962
Authors: Nina Friis-Møller; Rainer Weber; Peter Reiss; Rodolphe Thiébaut; Ole Kirk; Antonella d'Arminio Monforte; Christian Pradier; Linda Morfeldt; Silvia Mateu; Matthew Law; Wafaa El-Sadr; Stephan De Wit; Caroline A Sabin; Andrew N Phillips; Jens D Lundgren Journal: AIDS Date: 2003-05-23 Impact factor: 4.177
Authors: Erik Ehinger; Yanal Ghosheh; Akula Bala Pramod; Juan Lin; David B Hanna; Karin Mueller; Christopher P Durant; Livia Baas; Qibin Qi; Tao Wang; Konrad Buscher; Kathryn Anastos; Jason M Lazar; Wendy J Mack; Phyllis C Tien; Mardge H Cohen; Igho Ofotokun; Stephen Gange; Sonya L Heath; Howard N Hodis; Russell P Tracy; Alan L Landay; Robert C Kaplan; Klaus Ley Journal: Cardiovasc Res Date: 2021-03-21 Impact factor: 13.081